Mitiglinide

Source: Wikipedia, the free encyclopedia.
Mitiglinide
Clinical data
Trade namesGlufast
AHFS/Drugs.comInternational Drug Names
Routes of
administration		By mouth (tablets)
ATC code
Identifiers
  • (−)-(2S,3a,7a-cis)-α-Benzylhexahydro-γ-oxo-2-isoindolinebutyric acid
JSmol)
  • O=C(O)[C@@H](Cc1ccccc1)CC(=O)N3C[C@H]2CCCC[C@H]2C3
  • InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1 checkY
  • Key:WPGGHFDDFPHPOB-BBWFWOEESA-N checkY
 ☒NcheckY (what is this?)  (verify)

Mitiglinide (

type 2 diabetes.[2]

Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium KATP channels in pancreatic β cells.

Dosage

Mitiglinide is delivered in tablet form.

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names (Rec. INN): List 40" (PDF). World Health Organization. p. 187. Retrieved 10 November 2016.
  2. S2CID 73318104
    .

External links